MacuLogix Inc. has entered into an international distribution agreement with Clarion Medical Technologies, a provider of medical and aesthetic equipment and consumables.
Clarion will add the AdaptDx automated dark adaptometer to its Vision Division’s portfolio of products.
“We are very pleased to partner with Clarion to expand our reach into Canada,” Armond Dantino, MacuLogix vice president of sales, said in a press release. “Bringing the AdaptDx to Canada is critical to preserving vision, as AMD accounts for 90% of new cases of legal blindness in Canada, according to the Canadian Ophthalmological Society.”
The AdaptDx is a dark adaptometer that can detect AMD at the subclinical stage, before structural changes in the retina become visible, MacuLogix said in the release. Research has shown that using the AdaptDx can improve diagnostic sensitivity by detecting the disease with 90% accuracy at least 3 years before structural changes in the retina are visible.